NEW YORK, NY / ACCESSWIRE / September 19, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Latch, Inc. f/k/a TS Innovation Acquisitions Corp. (NASDAQ:LTCH)
Investors Affected : May 13, 2021 - August 25, 2022
A class action has commenced on behalf of certain shareholders in Latch, Inc f/k/a TS Innovation Acquisitions Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there were unreported sales arrangements related to hardware devices; (2) as a result, the Company had improperly recognized revenue throughout fiscal 2021 and first quarter 2022; (3) there were material weaknesses in Latch's internal control over financial reporting related to revenue recognition; (4) as a result of the foregoing, Latch would restate financial statements for fiscal 2021 and first quarter 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/latch-inc-f-k-a-ts-innovation-acquisitions-corp-loss-submission-form/?id=31923&from=1
Abbott Laboratories (NYSE:ABT)
This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.
A class action has commenced on behalf of certain shareholders in Abbott Laboratories. According to the filed complaint, defendants touted the strength of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration ("FDA") health, safety, and manufacturing regulations. The complaint further alleges that defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott's infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility.
Shareholders may find more information at https://securitiesclasslaw.com/securities/abbott-laboratories-loss-submission-form/?id=31923&from=1
Sema4 Holdings, Corp. (NASDAQ:SMRF)
Investors Affected : March 14, 2022 - August 15, 2022
A class action has commenced on behalf of certain shareholders in Sema4 Holdings, Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there was a significant risk that Sema4 would reverse a material amount of previously recognized revenue that it could not recoup from third party payors; (2) the Company was experiencing declining selling prices for its reproductive health segment; (3) as a result of the foregoing, Sema4's financial results would be adversely affected; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/sema4-holdings-corp-loss-submission-form/?id=31923&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm